3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
456
Pancreatic Neoplasms
363
Stomach Neoplasms
246
Carcinoma, Hepatocellular
231
Carcinoma, Non-Small-Cell Lung
164
Colonic Neoplasms
145
Esophageal Neoplasms
133
Neoplasms
115
Neoplasm Metastasis
114
Ovarian Neoplasms
111
Rectal Neoplasms
106
Liver Neoplasms
101
Breast Neoplasms
99
Lung Neoplasms
78
Melanoma
76
Squamous Cell Carcinoma of Head and Neck
70
Gastrointestinal Neoplasms
58
Endometrial Neoplasms
58
Carcinoma, Renal Cell
54
Uterine Cervical Neoplasms
52
Cholangiocarcinoma
52
Biliary Tract Neoplasms
52
Triple Negative Breast Neoplasms
49
Head and Neck Neoplasms
48
Sarcoma
46
Prostatic Neoplasms
45
Esophageal Squamous Cell Carcinoma
39
Urinary Bladder Neoplasms
34
Small Cell Lung Carcinoma
31
Carcinoma
29
Interventions
trifluridine tipiracil drug combination
1
reolysin
1
atezolizumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Anal Cancer Metastatic
×
Gastrointestinal
×
Clear all
NCT07280377
2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2
Active not recruiting
122 enrolled